Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable by Wu Helena T., Hsu Vanessa, Win Shwe, Xing Yan

Subjects: Get full text

Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy by Minfeng Yang, Shiqiang Hou, Yao Chen, Hongzhao Chen, Minjie Chu, Song-Bai Liu

“…Abstract Cancer immunotherapy has attracted great attention as a potential therapeutic approach for advanced malignancies due to its promising survival benefits. …”
Get full text

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy by Youmei Xiao, Zhuoying He, Wanqiong Li, Danhong Chen, Xiaoshuang Niu, Xin Yang, Wenxuan Zeng, Mengfan Wang, Yuzhen Qian, Ye Su, Feiyu Luo, Guanyu Chen, Juan Liu, Xinghua Sui, Xiuman Zhou, Yanfeng Gao

Get full text

Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens by Jie Jiang, Feng-Ying Huang, Shu-Zhen Dai, Guang-Hong Tan, Ming-Hui Chen, Hengyu Chen, Wu-Ping Zheng, Ri-Hong Wu, Weijing Xie

Get full text

Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? by Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck

Get full text

Perceptions in 3.6 Million Web-Based Posts of Online Communities on the Use of Cancer Immunotherapy: Data Mining Using BERTopic by Xingyue Wu, Chun Sing Lam, Ka Ho Hui, Herbert Ho-fung Loong, Keary Rui Zhou, Chun-Kit Ngan, Yin Ting Cheung

Get full text

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…The generation of TCR-like antibody and its CAR-T cells provides the state-of-the-art platform and proof-of-concept validation to broaden the scope of target antigen recognition and sheds light on the development of novel therapeutics for cancer immunotherapy.…”
Get full text

Harnessing amino acid pathways to influence myeloid cell function in tumor immunity by Jiongli Pan, Yi Lin, Xinyuan Liu, Xiaozhen Zhang, Tingbo Liang, Xueli Bai

Subjects: Get full text

Profile of STING agonist and inhibitor research: a bibliometric analysis by Xuemei Wang, Qian Wang, Yidan Gao, Lijuan Jiang, Lingli Tang

Subjects: Get full text

CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens by Sara W. Feigelson, Tali Dadosh, Nehora Levi, Anita Sapoznikov, Hadas Weinstein-Marom, Hadas Weinstein-Marom, Dayana Blokon-Kogan, Dayana Blokon-Kogan, Yahel Avraham, Tamar Unger, Gideon Gross, Gideon Gross, Rony Dahan, Ronen Alon

Subjects: “…cancer immunotherapy…”
Get full text

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells by Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti‑in, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Mutita Junking, Jatuporn Sujjitjoon, Pa‑thai Yenchitsomanus, Aussara Panya

Get full text

A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types by Zhen Zeng, Tianbei Zhang, Jiajia Zhang, Shuai Li, Sydney Connor, Boyang Zhang, Yimin Zhao, Jordan Wilson, Dipika Singh, Rima Kulikauskas, Candice D. Church, Thomas H. Pulliam, Saumya Jani, Paul Nghiem, Suzanne L. Topalian, Patrick M. Forde, Drew M. Pardoll, Hongkai Ji, Kellie N. Smith

Get full text

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells by Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti-in, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Mutita Junking, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Aussara Panya

Get full text

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy by Xia Liu, Emily Shaw, Fusheng Si, Guangyong Peng, Yan Tao, Feiya Ma, David Bagley, Yuanqin Zhang

“…Therefore, a better understanding of the molecular mechanism responsible for T cell senescence in the TME and development of novel strategies to prevent effector T cell senescence are urgently needed for cancer immunotherapy.Methods Senescent T cell populations in the TMEs in mouse lung cancer, breast cancer, and melanoma tumor models were evaluated. …”
Get full text

The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer by Si Chen, Caihong Yao, Na Tian, Chunying Zhang, Yuemei Chen, Xuting Wang, Yue Jiang, Tonghao Zhang, Tingting Zeng, Yali Song

“…Notable impacts on the immune microenvironment include changes in immune cell function and the regulation of immune checkpoints, offering insights into potential targets for cancer immunotherapy. Discussion This study highlights the complex relationship between chronic infections and cancer development, presenting new opportunities for cancer immunotherapy by understanding their effects on the immune microenvironment. …”
Get full text

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care by Drew M Pardoll, Suzanne L Topalian

Get full text

Exosomes, their sources, and possible uses in cancer therapy in the era of personalized medicine by Tomas Zemanek, Lubos Danisovic, Andreas Nicodemou

Get full text

Recent advances of nanovaccines on cancer theranostics by Xiaobing Yuan, Xiaobing Yuan, Xiaobing Yuan, Tianyou Xu, Mubashir Hussain, Bin Liu, Jianwei Zhu, Jianwei Zhu

“…This paper reviewed the research progress of some nanovaccines in cancer immunotherapy, including polymer nanoparticle vaccine, liposome nanoparticle vaccine, cell-based nanoparticle vaccine, inorganic nanoparticle vaccine, adjuvant and auxiliary work. …”
Get full text

Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma by Mayuna Nakamura, Yuka Tanaka, Keishi Hakoda, Masahiro Ohira, Tsuyoshi Kobayashi, Kenji Kurachi, Kouichi Tamura, Hideki Ohdan

“…Recently, cell-based immunotherapy using natural killer (NK) cells has attracted considerable attention in cancer immunotherapy. NK cells generated from induced pluripotent stem cells (iPSCs) are a new option for use as an NK cell resource. …”
Get full text

Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites by Yun Teng, Chao Luo, Xiaolan Qiu, Jingyao Mu, Mukesh K. Sriwastva, Qingbo Xu, Minmin Liu, Xin Hu, Fangyi Xu, Lifeng Zhang, Juw Won Park, Jae Yeon Hwang, Maiying Kong, Zhanxu Liu, Xiang Zhang, Raobo Xu, Jun Yan, Michael L. Merchant, Craig J. McClain, Huang-Ge Zhang

“…Here we investigate the impact of plant-derived nanoparticles (PNP) on gut microbiota and metabolites in context of cancer immunotherapy with the humanized gnotobiotic mouse model. …”
Get full text